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Individuals, families, health plans and governments are struggling with the growing importance of managing chronic,
non-communicable diseases. People in many countries are living longer and thus are facing many years of managing
hypertension, diabetes and hyperlipidemia – often complicated by obesity, declining physical activity and changing
diets. The financial burden this places on governments, employers, and individuals purchasing health care services is
growing and solutions are being sought on how to both finance this care and deliver the best care possible. New
ideas are emerging that look to newfound resources, and one untapped resource increasingly being utilized is the
clinical pharmacist. After many years being primarily involved in medication supply-chain management, the assistance
that highly skilled pharmacists can provide medical providers and their patients is now being recognized. In order to
realize fully the benefits of clinical pharmacists, governments, health plans and medical providers are taking a second
look at the wisdom of maintaining the long-standing policy of compensating pharmacists only for filling prescriptions.
Background
The recent IJHPR article by Hila Yariv [1], “The Case of
Pharmacist Prescribing Policy in Israel”, speaks well to
the professional and policy difficulties encountered in
finding reasonable solutions to increasing demands for
access to quality health care services. Whereas access to
medications may be the single biggest concern of most
low and middle resource countries, countries of all re-
source levels are beginning to understand the need for
better management of complicated chronic illnesses and
the pressures this puts on provider and financial re-
sources [2, 3]. The partial Israeli response to this pres-
sure is referred to as pharmacy prescribing in Yariv’s
article. This commentary looks at a much broader role
that pharmacists can play in ameliorating unmet health
care needs, not just by increasing access to more
medications.
While medication use is often held to be essential to
the mitigation of the human diseases, there are health
policies, health care provider education standards, pro-
fessional society policies, human behaviours, financial
restraints, and environmental factors that prevent na-
tions from realizing the full benefit that medications
promise to provide. Much has been written that speaks
to negotiating lower drug prices, restricting drug formu-
laries, increasing patient cost-sharing, and broadening
the use of generic drugs as key strategies to curbing drug
costs. Yet, even with these tools in place, the goal of
achieving improved health outcomes, while at the same
time controlling drug costs, has been elusive. Well
trained and well-meaning medical and pharmacy pro-
viders find themselves overwhelmed with managing the
growing number of chronically ill patients, their pre-
scription needs and their consultation needs. This com-
mentary argues for reconsideration and repurposing of
pharmacists as key to achieving the dual goals of im-
proved health at an affordable cost that providers and
governments seek. Success in this endeavour [4] argu-
ably means setting aside long-held stereotypes of phar-
macy practice and focusing policy more stridently on
unmet patient needs and less on protection of traditional
health care practices.
The 20th Century saw pharmacy practice come of age
with the profession moving from a medication com-
pounding specialty to the more expedient dispensing of
drug manufacturers’ finished products. A vast array of
powerful and effective medications became more avail-
able and pharmacists and pharmacies became an import-
ant supply chain component of that service. With
finished products replacing the art of prescription
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compounding, pharmacists found that they were able to
spend important time with their patients and they fre-
quently became a first-stop trusted medication-use pa-
tient advisor and confidant. As time passed, however,
pharmacists faced increasing demands to process more
and more prescriptions and decreasing time to spend
with patients. The lucrative business of dispensing large
quantities of prescriptions generated significant reve-
nues, and immense pharmacy chains developed, largely
run by non-pharmacist shareholders. Drug manufac-
turers worked hard to influence medical providers to
write more prescriptions for their products and influ-
enced pharmacies to stock and dispense more of their
products. As with pharmacists, medical providers found
themselves pressured to see more patients in less time
and financially were discouraged from spending as much
time with their patients as they would have wanted. It
was increasingly more expedient to send a patient out of
the exam room with a new prescription than to take un-
compensated time to coach patients on wellness-
improving behaviours.
The medical-pharmaceutical complex
This prescription pipeline, sometimes referred in part as
a Medical-Pharmaceutical Complex, has influenced
medical providers to prescribe more and newer medica-
tions and pharmacists to stock and dispense them. The
prescription pipeline has served a number of purposes,
not the least of which being the improved chances of
drug manufacturers to see of a positive return on prod-
uct development costs. Direct to consumer advertising
(DTCA) by drug manufactures, where allowed, brings
even more pressure to bear on medical and pharmacy
providers to produce and fill more prescriptions. On
November 17, 2015, the American Medical Association
adopted policy that called for a ban on DTCA. Accord-
ing to AMA Board Chair-elect Patrice A. Harris, M.D.,
M.A., “Direct-to consumer advertising also inflates de-
mand for new and more expensive drugs, even when
these drugs may not be appropriate [5].” Drug formulary
committees for health systems and health insurance
plans are also heavily lobbied to add new and often more
expensive medications to their formularies. While a
medication access pipeline is important to patient care,
proper drug therapy decisions must be evidence based
and coordinated between all members of the health care
team.
Medication management
We would all agree that having access to essential medi-
cations is a good thing. This said, it must be also argued
that while medication access is good, it is not nearly
enough. Access must be to the most clinically appropri-
ate medication, not just to medications that have been
marketed most successfully [6]. Medications that are
medically unnecessary; that are not sustainably afford-
able; that are dosed incorrectly; that are ineffective; that
are not coordinated between providers; or that generate
polypharmacy regimens that are too complex for pa-
tients to reasonably adhere to - all contribute to poor
outcomes and rising healthcare costs. The mismanage-
ment of medications is causative rather than preventa-
tive for hospitalizations, especially for the chronically ill
elderly. Because many chronically ill patients see more
than one prescribing medical provider, patients are also
exposed to a host of potential drug-drug conflicts and
fragmented drug therapy. Governments and health plans
continually address policies that would lower the cost of
prescriptions, but rarely do they speak to the cost sav-
ings associated with policies that incentivize improved
clinical medication management. One only needs to look
into the medicine cabinets of geriatric patients to
visualize the ubiquity and seriousness of this issue.
In the United States, where marketplace incentives are
historically preferred over government price controls,
pharmacists are increasingly being used as medication
consultants and health-team medication managers. Phar-
macists act as consults for both patients and providers.
They help reduce medication errors and preventable ad-
verse drug events. Pharmacists are being invited into clinic
primary care and specialty care teams to help medical pro-
viders manage greater numbers of complex therapy pa-
tients. In order to support these services in Washington
State, an Attorney General’s informal opinion and recent
legislation has confirmed that pharmacists must be
contracted by health plans to provide post-diagnosis medi-
cation management and not just compensated for filling
prescriptions [7].
For traditional dispensing pharmacies in the U.S., the
fee-for-service incentives to fill prescriptions has been
diminished by government and private health plans who
have reduced prescription dispensing fees in their efforts
lower drug expenditures [8]. As a consequence, however,
pharmacists find it increasing difficult to justify provid-
ing free clinical care and enough time with patients to
help them sort out their medication issues. In fact, sur-
veys show that reduced interaction time between a pa-
tient and a pharmacist has altered patient perspectives
as to what a desirable pharmacy visit entails. In most
cases patients express the opinion that a good pharmacy
visit provides fast service, low cost drugs, and in some
countries the provision of stay-in-your-automobile,
drive-through lanes or mail-order drug delivery. In low
resource countries most medications aren’t dispensed by
pharmacists at all. While these creative drug pipe-line
innovations may be convenient to busy patients they are
not likely to be conducive to well-managed medication
use and decreased health costs.
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Aligning incentives
Pharmacists graduating from colleges with clinical doc-
torates rightfully question why they are only compen-
sated for filling prescriptions when their professional
education is based on medication management services.
These pharmacists are exquisitely suited and profession-
ally obligated to work with patients and their medical
providers to make sure that patients are only taking the
medications that are clinically appropriate – often lead-
ing to a decision to reduce the patient’s prescription
load. Reducing a patient’s prescription burden, however,
reduces a pharmacist’s income. The integrity of pharma-
cist decision-making is compromised by this long-
standing health policy model and puts patients at greater
financial and clinical risk. For governments who have
and support public universities, their dollars used to
support pharmacist education seem arguably misspent if
that government’s health policies only incentivize their
pharmacy school graduates to sell more and more medi-
cations rather than using these experts to work with
medical providers to make sure limited resources are
spent on the most clinically and fiscally appropriate
medications.
A few models of pharmacy services
There are many models of patient-centric health care
teams that include pharmacists as core team members.
Many pharmacists, rather than dispensing medications,
have patients who are referred to them after a diagnosis
by a medical provider. Patients with chronic illnesses
can be managed by pharmacists after the diagnosis has
been made and thus free up medical providers to see the
more acutely ill. Classically, pharmacists who run antic-
oagulation management services for medical clinics, find
significantly more patients within INR goals and with
fewer bleeding or clotting mishaps and hospitalizations
[9]. Not only does this service result in better clinical
and financial outcomes, it frees medical providers for
other care services. Pharmacists may be employed as a
member of a medical clinic’s clinical team or contracted
externally. To be clear, medical providers still control
final prescribing decisions and pharmacists are not com-
peting for medical provider patients. Billable pharmacist
services for medication management most commonly
are predicated on formal referrals or on previously au-
thorized written protocols for prevention-based services
such as immunizations.
Conclusion
As governments, private health plans and patients strug-
gle with the financial burdens of managing chronic ill-
nesses, new and innovative methods of care delivery
need to be considered. The approach described in the
commentary has gained significant momentum and
makes use of an existing underutilized resource – clinical
pharmacists. It does require a progressive and inter-
professional program of pharmacy/medical education,
greater coordination of care, and health policies that
incentivize all members of the health care team to provide
collaborative primary care. Pharmacy graduates with
requisite clinical training are eager and able to help solve
the time and financial constraints facing primary care pro-
viders trying to manage the unabated number of individ-
uals who are chronically ill.
While one might expect strident medical opposition to
these pharmacist services, I have been told by physicians
who have practiced under these circumstances that they
wish that this arrangement had been established earlier.
Not only have they found that their work-life improved
with a pharmacist on their team, but they also expect
improvements in the health outcomes of their chronic-
ally ill patients. This benefits not only the patients but
those physicians for whom improved quality of care and
outcomes lead to improved medical provider payments
rather than revenue reductions.
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